TrialNet follow-on studies

The TrialNet Pathway to Prevention study screens for autoantibodies to four different components of the insulin-producing beta cells in the islets of the pancreas:

  • Insulin

  • Glutamic acid decarboxylase

  • Islet antigen-2

  • Zinc transporter 8

 

It also measures how well the body can control glucose levels after a glucose drink (the oral glucose test) to assess risk of disease. The results of these tests determine which of the following studies are offered to high-risk individuals:

  • Hydroxychloroquine (HCQ)

  • LIFT

Hydrodychloroquine (HCQ)

This study is for:

  • participants who are at least 3 years old AND

  • have two or more diabetes-related autoantibodies AND

  • have normal results on an oral glucose tolerance test (OGTT) AND

  • are able to swallow a whole capsule

  • NOT be pregnant or planning to become pregnant while in the study

  • NOT have any medical conditions that might make it unsafe for you to be in this study

About this study

We are testing the drug hydroxychloroquine (HCQ) to see if it can delay or prevent early stage T1D (stage 1) from progressing to abnormal glucose tolerance (stage 2) and ultimately prevent clinical diagnosis (stage 3). HCQ is already used to reduce symptoms and progression of other autoimmune diseases, such as rheumatoid arthritis and lupus. This is the first study to see if it can prevent or delay T1D.

For more information about this study

  • Contact us

Long-Term Investigative Follow-Up in TrialNet (LIFT) Study

This study is for:

About this study

LIFT aims to identify factors associated with preservation of pancreas function early in the course of T1D. This will improve our ability to develop treatments that protect the pancreas and improve glucose control in the first few years after diabetes is diagnosed.

 

Participation involves 6-monthly visits for oral glucose tests and blood sampling.

For more information about this study